Zhang, Haonan
Qiao, Anna
Yang, Dehua
Yang, Linlin
Dai, Antao
de Graaf, Chris
Reedtz-Runge, Steffen
Dharmarajan, Venkatasubramanian
Zhang, Hui
Han, Gye Won
Grant, Thomas D.
Sierra, Raymond G.
Weierstall, Uwe
Nelson, Garrett
Liu, Wei
Wu, Yanhong
Ma, Limin
Cai, Xiaoqing
Lin, Guangyao
Wu, Xiaoai
Geng, Zhi
Dong, Yuhui
Song, Gaojie
Griffin, Patrick R.
Lau, Jesper
Cherezov, Vadim
Yang, Huaiyu
Hanson, Michael A.
Stevens, Raymond C.
Zhao, Qiang
Jiang, Hualiang
Wang, Ming-Wei
Wu, Beili
Article History
Received: 9 January 2017
Accepted: 12 April 2017
First Online: 17 May 2017
Change Date: 19 June 2017
Change Type: Correction
Change Details: The Reviewer Information section was corrected.
Competing interests
: S.R.-R., X.W. and J.L. are employees of Novo Nordisk, a pharmaceutical company focused on class B GPCRs for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. The other authors declare no competing financial interests.